SCHEMBL238442

SCHEMBL238442

COc1ccccc1C(O)(OC)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.43
CA1 P00915 3/20 0.43
CA2 P00918 3/20 0.43
CA12 O43570 2/20 0.43
CA7 P43166 2/20 0.43
CA9 Q16790 2/20 0.43
CA14 Q9ULX7 2/20 0.43
CA4 P22748 1/20 0.43
NR3C2 P08235 1/20 0.43
GAA P10253 4/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
TP53 P04637 1/20 0.41
TSHR P16473 1/20 0.41
HTT P42858 3/20 0.40
CASR P41180 1/20 0.40
ENPP2 Q13822 1/20 0.38
ORAI1 Q96D31 1/20 0.37
ORAI2 Q96SN7 1/20 0.37
ORAI3 Q9BRQ5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18550496 0.86 NFE2L2 (0.41) ALDH1A1CA1CA2CA12CA7
SCHEMBL6568167 0.81 CYP19A1 (0.51) ALDH1A1CA1CA2CA12CA7
SCHEMBL4599958 0.81 CYP19A1 (0.48) ALDH1A1CA1CA2CA12CA7
SCHEMBL28117527 0.80 CES1 (0.47) ALDH1A1CA4KMT2ATSHRSMN1; SMN2
SCHEMBL18545738 0.79 CASR (0.51) ALDH1A1CA1CA2CA12CA7
SCHEMBL221217 0.77 CA1 (0.46) ALDH1A1CA1CA2CA12CA7
SCHEMBL221587 0.77 CA1 (0.46) ALDH1A1CA1CA2CA12CA7
SCHEMBL6257499 0.77 CA1 (0.46) ALDH1A1CA1CA2CA12CA7
SCHEMBL7713128 0.77 CA1 (0.46) ALDH1A1CA1CA2CA12CA7
SCHEMBL28318661 0.77 CA1 (0.52) ALDH1A1CA1CA2CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104178134-B Novel luminescent material 辽宁大学 2017-01-25 CN claimed
US-11796919-B2 Resist pattern formation method OSAKA UNIVERSITY (JP) 2023-10-24 US disclosed
CN-111562720-B Photo-sensitized chemically amplified resist material, pattern forming method, semiconductor device, mask for lithography, and template for nanoimprint 东京毅力科创株式会社 2023-09-29 CN disclosed
CN-113816837-B Synthesis method of 4,4' -dimethoxy triphenylchloromethane 连云港冠昕医药科技有限公司 2023-09-19 CN disclosed
US-20210216016-A1 RESIST PATTERN FORMATION METHOD OSAKA UNIVERSITY (JP) 2021-07-15 US disclosed
EP-3809206-A1 RESIST PATTERN FORMATION METHOD Osaka University (JP) 2021-04-21 EP disclosed
CN-112272798-A Resist pattern forming method 国立大学法人大阪大学 2021-01-26 CN disclosed
EP-3109703-B1 PHOTOSENSITIZATION CHEMICAL-AMPLIFICATION TYPE RESIST MATERIAL, AND METHOD FOR FORMING PATTERN USING SAME TOKYO ELECTRON LTD (JP) 2020-12-30 EP disclosed
CN-111562720-A Photosensitizing chemically amplified resist material, method for forming pattern, semiconductor device, mask for lithography, and template for nanoimprint 东京毅力科创株式会社 2020-08-21 CN disclosed
CN-106030417-B Photosensitizing chemically amplified resist material, method for forming pattern using same, semiconductor device, mask for lithography, and method for manufacturing template for nanoimprinting 东京毅力科创株式会社 2020-02-28 CN disclosed
US-20030203957-A1 Selected fused pyrrolocarbazoles CEPHALON, INC. 2003-10-30 US disclosed
US-6630500-B2 Treating angiogenic disorders CEPHALON, INC. 2003-10-07 US disclosed
EP-1311263-A2 FUSED PYRROLOCARBAZOLES AGAINST INFLAMMATION CEPHALON, INC. (US) 2003-05-21 EP disclosed
US-20020061920-A1 Selected fused pyrrolocarbazoles CEPHALON, INC. 2002-05-23 US disclosed
WO-2002017914-A2 FUSED PYRROLOCARBAZOLES AGAINST INFLAMMATION CEPHALON, INC. (US) 2002-03-07 WO disclosed
EP-1165508-A1 ANTICANCER CALCIUM CHANNEL BLOCKERS Gray, Lloyd S. (US) 2002-01-02 EP disclosed
WO-2000059882-A9 ANTICANCER CALCIUM CHANNEL BLOCKERS GRAY LLOYD S (US) 2001-11-29 WO disclosed
WO-2000059882-A1 ANTICANCER CALCIUM CHANNEL BLOCKERS GRAY LLOYD S (US) 2000-10-12 WO disclosed
EP-0934260-A1 N ALPHA-2-(4-NITROPHENYLSULFONYL)ETHOXYCARBONYL-AMINO ACIDS Hyundai Pharm. Ind. Co., Ltd. (KR) 1999-08-11 EP disclosed
WO-1998017638-A1 Nα-2-(4-NITROPHENYLSULFONYL)ETHOXYCARBONYL-AMINO ACIDS HYUNDAI PHARM. IND. CO., LTD. (KR) 1998-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061920-A1 Selected fused pyrrolocarbazoles CYP11B2, PC, CYP4F3 ALDH1A1 498/4885CA1 3062/4885CA2 2093/4885
US-20030203957-A1 Selected fused pyrrolocarbazoles CYP11B2, PC, CYP4F3 ALDH1A1 498/4885CA1 3062/4885CA2 2093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.